Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleClinical Investigation

Progression from Unilateral to Bilateral Parkinsonism in Early Parkinson Disease: Implication of Mesocortical Dopamine Dysfunction by PET

Shunsuke Yagi, Etsuji Yoshikawa, Masami Futatsubashi, Masamichi Yokokura, Yujiro Yoshihara, Tatsuo Torizuka and Yasuomi Ouchi
Journal of Nuclear Medicine August 2010, 51 (8) 1250-1257; DOI: https://doi.org/10.2967/jnumed.110.076802
Shunsuke Yagi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Etsuji Yoshikawa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masami Futatsubashi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masamichi Yokokura
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yujiro Yoshihara
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tatsuo Torizuka
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yasuomi Ouchi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    11C-CFT PET images and ROI setting. (A) Irregular ROIs, drawn bilaterally on concerned regions on MR images, were placed on corresponding PET images. (B) PD patient with longer conversion period from HY stage 1 to HY stage 2. (C) PD patient with shorter conversion period from HY stage 1 to HY stage 2. Arrow indicates reduction in 11C-CFT binding in nucleus accumbens. Color bar indicates quantified level of RI (from 0 to 3). Ac = nucleus accumbens; Cd = caudate; Ce = cerebellum; DP = dorsal putamen; O = orbitofrontal cortex; VP = ventral putamen.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    Correlations between UPDRS score at HY stage 1 and 11C-CFT RI values. Dashed lines for ○ and chain lines for ▲ show all tendencies of negative correlations. ○ = affected side; ▲ = unaffected side.

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    Correlations between conversion interval (y) and 11C-CFT RI values. Straight lines for ▲ show significant correlations (P < 0.05). ○ = affected side; ▲ = unaffected side.

Tables

  • Figures
    • View popup
    TABLE 1.

    Characteristics of PD Patients

    Patient no.SexAge (y)Duration of illness (mo)*UPDRS totalAffected sideInitial symptom
    1F441811 (2/3/6)LRigidity
    2F551213 (2/3/8)LRigidity/tremor (UL/LL)
    3M671414 (1/2/11)RTremor (UL)
    4F602416 (2/3/11)RTremor (UL/LL)
    5M582516 (4/6/6)RRigidity/tremor (UL)
    6F581017 (2/5/10)RRigidity/tremor (UL)
    7F71918 (2/4/12)RRigidity/tremor (UL)
    8M563318 (4/4/10)RRigidity/tremor (UL/LL)
    9F73420 (2/2/16)LRigidity/tremor (UL/LL)
    10M64621 (2/4/15)RRigidity
    11M431221 (2/6/13)LRigidity/tremor (UL)
    12F572825 (4/5/16)RRigidity/tremor (UL)
    • ↵* Duration between disease onset and PET examination.

    • UPDRS scores in parentheses are mentation/activities of daily living/motor examination.

    • UL = upper limb; LL = lower limb.

    • View popup
    TABLE 2.

    Levels of 11C-CFT Uptake in PD Patients and Controls

    Putamen
    Nucleus accumbensCaudateVentralDorsalOrbitofrontal
    SubjectAffected sideUnaffected sideAffected sideUnaffected sideAffected sideUnaffected sideAffected sideUnaffected sideAffected sideUnaffected side
    Healthy control (n = 8)2.08 ± 0.202.23 ± 0.242.36 ± 0.292.51 ± 0.330.25 ± 0.08
    PD patient (n = 12)1.29 ± 0.301.42 ± 0.251.48 ± 0.381.75 ± 0.301.18 ± 0.361.43 ± 0.370.99 ± 0.351.40 ± 0.470.17 ± 0.040.18 ± 0.06
    % reduction38%32%34%22%50%39%61%45%34%28%
    • Each value is expressed as ratio index. % reduction denotes level of change in ratio index of PD patient compared with healthy control.

    • View popup
    TABLE 3.

    Details of PD Patients at Time of Progression to HY Stage 2

    Patient no.Interval (y)*% Increase of UPDRS†Levodopa (mg/d)Dopamine agonist (mg/d)Anticholinergic agent (mg/d)Selegiline (mg/d)
    15732000.54—
    251001000.54—
    32712000.7545
    43381000.54—
    51.8752000.7545
    64651000.54—
    74.4331000.54—
    83331000.54—
    92401000.54—
    10——————
    111.5482000.7545
    120.5442000.7545
    • ↵* Interval of conversion from HY stage 1 to stage 2.

    • ↵† % increase of UPDRS = [UPDRS at HY stage 2 (“on” state) − initial UPDRS at HY stage 1]/initial UPDRS at HY stage 1 × 100.

    • No information was available for patient 10 because patient dropped out of study.

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 51 (8)
Journal of Nuclear Medicine
Vol. 51, Issue 8
August 1, 2010
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Progression from Unilateral to Bilateral Parkinsonism in Early Parkinson Disease: Implication of Mesocortical Dopamine Dysfunction by PET
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Progression from Unilateral to Bilateral Parkinsonism in Early Parkinson Disease: Implication of Mesocortical Dopamine Dysfunction by PET
Shunsuke Yagi, Etsuji Yoshikawa, Masami Futatsubashi, Masamichi Yokokura, Yujiro Yoshihara, Tatsuo Torizuka, Yasuomi Ouchi
Journal of Nuclear Medicine Aug 2010, 51 (8) 1250-1257; DOI: 10.2967/jnumed.110.076802

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Progression from Unilateral to Bilateral Parkinsonism in Early Parkinson Disease: Implication of Mesocortical Dopamine Dysfunction by PET
Shunsuke Yagi, Etsuji Yoshikawa, Masami Futatsubashi, Masamichi Yokokura, Yujiro Yoshihara, Tatsuo Torizuka, Yasuomi Ouchi
Journal of Nuclear Medicine Aug 2010, 51 (8) 1250-1257; DOI: 10.2967/jnumed.110.076802
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • Acknowledgments
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Subregional Patterns of Preferential Striatal Dopamine Transporter Loss Differ in Parkinson Disease, Progressive Supranuclear Palsy, and Multiple-System Atrophy
  • Google Scholar

More in this TOC Section

  • The Use of Maximum-Intensity Projections and Deep Learning Adds Value to the Fully Automatic Segmentation of Lesions Avid for [18F]FDG and [68Ga]Ga-PSMA in PET/CT
  • Additive Value of [68Ga]Ga-RM26 PET/CT to [68Ga]Ga-PSMA-617 PET/CT in Detecting Pelvic Lymph Node Metastasis in Prostate Cancer: A Prospective, Single-Center, Phase II Study
  • Assessment of [177Lu]Lu-DOTATATE Dosimetry from High-Speed Whole-Body Recordings Provided by a 360° Cadmium–Zinc–Telluride Camera Compared with Results from a Conventional Anger-Camera Protocol
Show more Clinical Investigation

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire